A team of researchers led by Dr Peter Crowley at the National University of Ireland Galway has revealed in intricate detail how a drug-like molecule can explore the surface of a protein.
The pioneering work was published by Nature Chemistry online (Sunday, 29 April) and will appear in the June issue of the journal. It was found that molecules scout around the protein surface, moving from one location to another constantly examining their surroundings.
For the past thirty years, drug design has been dominated by the search for small molecules that fit perfectly into a protein’s active site and modify its activity. Recently, the focus of attention has shifted to molecules that recognise and bind to the protein surface. Such molecules can camouflage the protein and prevent it binding to other proteins. Knowledge of these interactions is essential to the development of therapies that target undesirable protein interactions such as occur in Alzheimer’s disease.
“Inside every cell thousands of different proteins work together, like the parts in a machine, to sustain life. How proteins stick to one another and to other molecules is a crucial piece in the complicated puzzle of biochemistry and often the key to effective drugs”, explains Dr Crowley.
The researchers chose a negatively charged molecule called calixarene and a protein with lots of lysine amino acids, which are positive. The opposite charges cause a force of attraction between them. Using sophisticated analytical methods, Nuclear Magnetic Resonance (NMR) spectroscopy and X-ray crystallography, Dr Crowley and colleagues were able to visualise how the calixarene sticks to the protein surface.
“Another feature of the calixarene is its bowl-shape. Lysine can fit snugly inside the calixarene, which ensures that an interaction takes place”, adds Dr Crowley. “It turns out that the calixarene binds to several different lysines and explores the protein surface by hopping from one lysine to another. The result is exciting because it adds a new dimension to our understanding and provides drug designers with an alternative strategy.”
Dr Crowley emphasised the importance of funding basic research and acknowledged the support of the National University of Ireland Galway and Science Foundation Ireland. The project was a collaborative effort that involved the European Synchrotron Radiation Facility and Dr Amir Khan at Trinity College Dublin.
Keywords: NUI GALWAY ‘Scouting’ Molecules New Direction for Drug Development
Author: Marketing and Communications Office, NUI Galway